Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)

Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Patient-level data were pooled from 11 pro...

Descripción completa

Detalles Bibliográficos
Autores: Müller-Wieland, Dirk|||0000-0002-8807-6442, Freemantle, Nick|||0000-0001-5807-5740, Bonadonna, Riccardo C.|||0000-0002-9809-1005, Mauquoi, Celine, Bigot, Gregory, Bonnemaire, Mireille, Gourdy, Pierre|||0000-0002-5362-3813, Mauricio, Didac|||0000-0002-2868-0250
Tipo de recurso: artículo
Fecha de publicación:2023
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:303458
Acceso en línea:https://ddd.uab.cat/record/303458
https://dx.doi.org/urn:doi:10.1007/s13300-022-01356-3
Access Level:acceso abierto
Palabra clave:Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
id ES_0ddff7b3e112fdbb54a99cd314cc643e
oai_identifier_str oai:ddd.uab.cat:303458
network_acronym_str ES
network_name_str España
repository_id_str
spelling Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)Results from the REALI Pooled DatabaseMüller-Wieland, Dirk|||0000-0002-8807-6442Freemantle, Nick|||0000-0001-5807-5740Bonadonna, Riccardo C.|||0000-0002-9809-1005Mauquoi, CelineBigot, GregoryBonnemaire, MireilleGourdy, Pierre|||0000-0002-5362-3813Mauricio, Didac|||0000-0002-2868-0250Basal insulin analoguesBasal insulin switchingInsulin glargine 300 U/mlNeutral protamine Hagedorn insulinPooled databaseRoutine clinical practiceType 2 diabetes mellitusUsing pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Patient-level data were pooled from 11 prospective, open-label, 24-week studies. Participants were classified according to the type of prior BI. Of the 4463 participants, 1282 (28.7%) were pre-treated with neutral protamine Hagedorn (NPH) insulin and 2899 (65.0%) with BI analogues (BIAs), and 282 (6.3%) had undetermined prior BI. There were no meaningful differences in baseline characteristics between subgroups, except for a higher prevalence of diabetic neuropathy in the NPH subgroup (21.6% versus 7.8% with BIAs). Mean ± standard deviation haemoglobin A1c (HbA1c) decreased from 8.73 ± 1.15% and 8.35 ± 0.95% at baseline to 7.71 ± 1.09% and 7.82 ± 1.06% at week 24 in the NPH and BIA subgroups, respectively. Least squares (LS) mean change in HbA1c was - 0.85% (95% confidence interval - 0.94 to - 0.77) in NPH subgroup and - 0.70% (- 0.77 to - 0.64) in BIA subgroup, with a LS mean absolute difference between subgroups of 0.16 (0.06-0.26; p = 0.002). Gla-300 mean daily dose was slightly increased at week 24 by 0.07 U/kg/day (approximately 6 U/day) in both subgroups. Incidences of symptomatic and severe hypoglycaemia were low, without body weight change. Irrespective of previous BI therapy (NPH insulin or BIAs), switching to Gla-300 improved glycaemic control without weight gain and with low symptomatic and severe hypoglycaemia incidences. However, a slightly greater glucose-lowering effectiveness was observed in people pre-treated with NPH insulin.Universitat Autònoma de Barcelona 22023-01-0120232023-01-01Articlehttp://purl.org/coar/resource_type/c_6501VoRhttp://purl.org/coar/version/c_970fb48d4fbd8a85info:eu-repo/semantics/articleapplication/pdfhttps://ddd.uab.cat/record/303458https://dx.doi.org/urn:doi:10.1007/s13300-022-01356-3reponame:Dipòsit Digital de Documents de la UABinstname:Universitat Autònoma de BarcelonaInglésengopen accesshttp://purl.org/coar/access_right/c_abf2Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.https://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/openAccessoai:ddd.uab.cat:3034582026-06-06T12:50:31Z
dc.title.none.fl_str_mv Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
Results from the REALI Pooled Database
title Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
spellingShingle Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
Müller-Wieland, Dirk|||0000-0002-8807-6442
Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
title_short Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
title_full Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
title_fullStr Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
title_full_unstemmed Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
title_sort Glycaemic Control in People with Type 2 Diabetes Mellitus Switching from Basal Insulin to Insulin Glargine 300 U/ml (Gla-300)
dc.creator.none.fl_str_mv Müller-Wieland, Dirk|||0000-0002-8807-6442
Freemantle, Nick|||0000-0001-5807-5740
Bonadonna, Riccardo C.|||0000-0002-9809-1005
Mauquoi, Celine
Bigot, Gregory
Bonnemaire, Mireille
Gourdy, Pierre|||0000-0002-5362-3813
Mauricio, Didac|||0000-0002-2868-0250
author Müller-Wieland, Dirk|||0000-0002-8807-6442
author_facet Müller-Wieland, Dirk|||0000-0002-8807-6442
Freemantle, Nick|||0000-0001-5807-5740
Bonadonna, Riccardo C.|||0000-0002-9809-1005
Mauquoi, Celine
Bigot, Gregory
Bonnemaire, Mireille
Gourdy, Pierre|||0000-0002-5362-3813
Mauricio, Didac|||0000-0002-2868-0250
author_role author
author2 Freemantle, Nick|||0000-0001-5807-5740
Bonadonna, Riccardo C.|||0000-0002-9809-1005
Mauquoi, Celine
Bigot, Gregory
Bonnemaire, Mireille
Gourdy, Pierre|||0000-0002-5362-3813
Mauricio, Didac|||0000-0002-2868-0250
author2_role author
author
author
author
author
author
author
dc.contributor.none.fl_str_mv Universitat Autònoma de Barcelona
dc.subject.none.fl_str_mv Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
topic Basal insulin analogues
Basal insulin switching
Insulin glargine 300 U/ml
Neutral protamine Hagedorn insulin
Pooled database
Routine clinical practice
Type 2 diabetes mellitus
description Using pooled data from the REALI European database, we evaluated the impact of previous basal insulin (BI) type on real-life effectiveness and safety of switching to insulin glargine 300 U/ml (Gla-300) in people with suboptimally controlled type 2 diabetes. Patient-level data were pooled from 11 prospective, open-label, 24-week studies. Participants were classified according to the type of prior BI. Of the 4463 participants, 1282 (28.7%) were pre-treated with neutral protamine Hagedorn (NPH) insulin and 2899 (65.0%) with BI analogues (BIAs), and 282 (6.3%) had undetermined prior BI. There were no meaningful differences in baseline characteristics between subgroups, except for a higher prevalence of diabetic neuropathy in the NPH subgroup (21.6% versus 7.8% with BIAs). Mean ± standard deviation haemoglobin A1c (HbA1c) decreased from 8.73 ± 1.15% and 8.35 ± 0.95% at baseline to 7.71 ± 1.09% and 7.82 ± 1.06% at week 24 in the NPH and BIA subgroups, respectively. Least squares (LS) mean change in HbA1c was - 0.85% (95% confidence interval - 0.94 to - 0.77) in NPH subgroup and - 0.70% (- 0.77 to - 0.64) in BIA subgroup, with a LS mean absolute difference between subgroups of 0.16 (0.06-0.26; p = 0.002). Gla-300 mean daily dose was slightly increased at week 24 by 0.07 U/kg/day (approximately 6 U/day) in both subgroups. Incidences of symptomatic and severe hypoglycaemia were low, without body weight change. Irrespective of previous BI therapy (NPH insulin or BIAs), switching to Gla-300 improved glycaemic control without weight gain and with low symptomatic and severe hypoglycaemia incidences. However, a slightly greater glucose-lowering effectiveness was observed in people pre-treated with NPH insulin.
publishDate 2023
dc.date.none.fl_str_mv 2
2023-01-01
2023
2023-01-01
dc.type.none.fl_str_mv Article
http://purl.org/coar/resource_type/c_6501
VoR
http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.openaire.fl_str_mv info:eu-repo/semantics/article
format article
dc.identifier.none.fl_str_mv https://ddd.uab.cat/record/303458
https://dx.doi.org/urn:doi:10.1007/s13300-022-01356-3
url https://ddd.uab.cat/record/303458
https://dx.doi.org/urn:doi:10.1007/s13300-022-01356-3
dc.language.none.fl_str_mv Inglés
eng
language_invalid_str_mv Inglés
language eng
dc.rights.none.fl_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
dc.rights.openaire.fl_str_mv info:eu-repo/semantics/openAccess
rights_invalid_str_mv open access
http://purl.org/coar/access_right/c_abf2
https://creativecommons.org/licenses/by-nc/4.0/
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.source.none.fl_str_mv reponame:Dipòsit Digital de Documents de la UAB
instname:Universitat Autònoma de Barcelona
instname_str Universitat Autònoma de Barcelona
reponame_str Dipòsit Digital de Documents de la UAB
collection Dipòsit Digital de Documents de la UAB
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869403364241965056
score 15,811543

Similares en LA Referencia